These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 18801950)

  • 21. Voriconazole inhibition of vitamin A metabolism: are adverse events increased in cystic fibrosis patients?
    Cheng MP; Paquette K; Lands LC; Ovetchkine P; Théoret Y; Quach C
    Pediatr Pulmonol; 2010 Jul; 45(7):661-6. PubMed ID: 20575095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Voriconazole-associated myositis.
    Shanmugam VK; Matsumoto C; Pien E; Rosen J; Kumar P; Whelton S; Steen V
    J Clin Rheumatol; 2009 Oct; 15(7):350-3. PubMed ID: 20009971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Voriconazole compromises renal function in an elderly CDK patient with Candida albicans infection].
    Anastasio P; Marcarelli F; Bilancio G; Mele AA; De Santo NG
    G Ital Nefrol; 2010; 27(3):306-11. PubMed ID: 20540025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Idiosyncratic nature of voriconazole photosensitivity in children undergoing cancer therapy.
    Hansford JR; Cole C; Blyth CC; Gottardo NG
    J Antimicrob Chemother; 2012 Jul; 67(7):1807-9. PubMed ID: 22454488
    [No Abstract]   [Full Text] [Related]  

  • 25. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
    Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
    Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Voriconazole-induced blistering in the setting of graft versus host disease: A report of 2 patients.
    Conlon JD; Dauenhauer M; Tonkovic-Capin V; Talano J; Margolis D; Drolet BA; Fairley JA
    J Am Acad Dermatol; 2008 Mar; 58(3):484-7. PubMed ID: 18280346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pseudoporphyria induced by voriconazole.
    Sharp MT; Horn TD
    J Am Acad Dermatol; 2005 Aug; 53(2):341-5. PubMed ID: 16021136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phototoxic dermatoses in pediatric BMT patients receiving voriconazole.
    Goyal RK; Gehris RP; Howrie D; Cogley KM; Windreich RM; Venkataramanan R
    Pediatr Blood Cancer; 2014 Jul; 61(7):1325-8. PubMed ID: 24619922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy.
    Curigliano G; Formica V; De Pas T; Spitaleri G; Pietri E; Fazio N; de Braud F; Goldhirsch A
    Ann Oncol; 2006 Jul; 17(7):1174-5. PubMed ID: 16410362
    [No Abstract]   [Full Text] [Related]  

  • 30. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity.
    Miller DD; Cowen EW; Nguyen JC; McCalmont TH; Fox LP
    Arch Dermatol; 2010 Mar; 146(3):300-4. PubMed ID: 20083676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis.
    Kobayashi K; Kami M; Murashige N; Kishi Y; Fujisaki G; Mitamura T
    Haematologica; 2004 Nov; 89(11):ECR42. PubMed ID: 15533847
    [No Abstract]   [Full Text] [Related]  

  • 32. Toxic epidermal necrolysis as a complication of treatment with voriconazole.
    Huang DB; Wu JJ; Lahart CJ
    South Med J; 2004 Nov; 97(11):1116-7. PubMed ID: 15586606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Painful peripheral neuropathy associated with voriconazole use.
    Tsiodras S; Zafiropoulou R; Kanta E; Demponeras C; Karandreas N; Manesis EK
    Arch Neurol; 2005 Jan; 62(1):144-6. PubMed ID: 15642862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Voriconazole - applications and perspectives].
    Ruhnke M
    Mycoses; 2002; 45 Suppl 3():42-7. PubMed ID: 12690971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of voriconazole in the treatment of central nervous system blastomycosis.
    Ta M; Flowers SA; Rogers PD
    Ann Pharmacother; 2009 Oct; 43(10):1696-700. PubMed ID: 19724015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Voriconazole-induced neuropathy.
    Aksoy F; Akdogan E; Aydin K; Yilmaz M; Altunayoglu V; Sozen EE; Omay SB; Koksal I
    Chemotherapy; 2008; 54(3):224-7. PubMed ID: 18560230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case series of unilateral orbital aspergillosis in three cats and treatment with voriconazole.
    Smith LN; Hoffman SB
    Vet Ophthalmol; 2010 May; 13(3):190-203. PubMed ID: 20500720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utilisation, efficacy and safety of voriconazole: prospective, non-interventional study on treatment of IFIs in clinical practice.
    Heinz WJ; Silling G; Böhme A
    Curr Med Res Opin; 2011 Feb; 27(2):335-42. PubMed ID: 21155707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect.
    Alkan Y; Haefeli WE; Burhenne J; Stein J; Yaniv I; Shalit I
    Clin Infect Dis; 2004 Sep; 39(6):e49-52. PubMed ID: 15472801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
    Howard A; Hoffman J; Sheth A
    Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.